| 2026-01-21 | +86.3% | M&A | Seeking Alpha | Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal |
| 2026-01-21 | +86.3% | legal | SEC EDGAR | LSTA 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-01-21 | +86.3% | M&A | Yahoo Finance | Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - Yahoo Finance |
| 2026-01-21 | +86.3% | news | Business Wire | LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - Business Wire |
| 2026-01-21 | +86.3% | M&A | Investing.com | Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com |
| 2026-01-21 | +86.3% | M&A | Investing.com | Kuva Labs to acquire Lisata Therapeutics for $4 per share - Investing.com |
| 2026-01-21 | +86.3% | M&A | citybiz | Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share - citybiz |
| 2026-01-21 | +86.3% | M&A | Proactive financial news | Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal - Proactive financial news |
| 2026-01-21 | +86.3% | M&A | TradingView | Lisata Therapeutics To Be Acquired By Kuva Labs For $4.00 Per Share In An All-Cash Tender Offer - TradingView |
| 2025-01-22 | -38.8% | news | Seeking Alpha | Lisata falls after mid-stage data for anticancer agent |
| 2026-04-15 | -26.6% | legal | SEC EDGAR | LSTA 8-K: 8.01 (SEC Filing) |
| 2026-04-15 | -26.6% | news | Stock Titan | Financing delays put Lisata Therapeutics (LSTA) tender offer by Kuva Labs in doubt - Stock Titan |
| 2026-04-15 | -26.6% | news | TipRanks | Lisata Therapeutics extends deadline for Kuva tender offer - TipRanks |
| 2022-09-16 | -24.6% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Lisata Therapeutics, Inc. (LSTA) - Zacks Investment Research |
| 2022-09-16 | -24.6% | analyst | TradingView | LSTA Forecast — Price Target — Prediction for 2027 - TradingView |
| 2022-09-16 | -24.6% | news | Zacks Investment Research | Should I buy Lisata Therapeutics, Inc. (LSTA) - Zacks Investment Research |
| 2022-09-15 | -20.2% | legal | SEC EDGAR | LSTA 8-K: 2.01, 3.03, 5.02, 5.03, 7.01 (SEC Filing) |
| 2022-09-15 | -20.2% | news | Stocktwits | LSTA: Lisata Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits |
| 2022-09-15 | -20.2% | news | TradingView | LSTA Stock Price and Chart — NASDAQ:LSTA - TradingView |
| 2026-03-09 | +19.6% | M&A | Proactive | Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances |
| 2026-03-09 | +19.6% | legal | SEC EDGAR | LSTA 8-K: 1.01, 7.01 (SEC Filing) |
| 2026-03-09 | +19.6% | news | PR Newswire | Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire |
| 2026-03-09 | +19.6% | M&A | TradingView | Lisata Therapeutics to Be Acquired by Kuva Labs in $5.00-Per-Share Tender Offer Plus $1.00 CVR - TradingView |
| 2026-03-09 | +19.6% | M&A | Proactive financial news | Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances - Proactive financial news |
| 2026-03-09 | +19.6% | news | Benzinga | Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga |
| 2026-03-06 | +19.6% | M&A | GlobeNewswire | Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. |
| 2026-03-06 | +19.6% | M&A | GlobeNewswire | Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewswire |
| 2022-09-14 | -17.5% | legal | SEC EDGAR | LSTA 8-K: 5.03, 5.07, 8.01 (SEC Filing) |
| 2025-08-07 | -12.9% | earnings | Seeking Alpha | Lisata Therapeutics GAAP EPS of -$0.54 beats by $0.11 |
| 2025-08-07 | -12.9% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-04-27 | -12.3% | legal | SEC EDGAR | LSTA 8-K: 1.01, 7.01, 8.01 (SEC Filing) |
| 2025-11-07 | -12.3% | news | Seeking Alpha | Lisata outlines Phase III certepetide trial preparations and targets milestone-rich 2026 amid expanded alliances |
| 2025-11-07 | -12.3% | earnings | Seeking Alpha | Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript |
| 2026-01-27 | +12.1% | expansion | GlobeNewswire | Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide |
| 2026-01-27 | +12.1% | legal | SEC EDGAR | LSTA 8-K: 8.01 (SEC Filing) |
| 2026-01-27 | +12.1% | news | Stock Titan | Cancer drug rights shift: Lisata takes back certepetide in China - Stock Titan |
| 2026-01-27 | +12.1% | expansion | Investing.com | Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com |
| 2026-01-27 | +12.1% | news | Proactive financial news | Lisata regains China rights to pancreatic cancer drug - Proactive financial news |
| 2026-04-13 | -11.8% | M&A | MSN | Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN |
| 2025-11-06 | -11.0% | earnings | Seeking Alpha | Lisata Therapeutics Non-GAAP EPS of -$0.49 beats by $0.05 |
| 2025-11-06 | -11.0% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-02-28 | -10.2% | earnings | Seeking Alpha | Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript |
| 2025-05-09 | -9.5% | earnings | Seeking Alpha | Lisata Therapeutics GAAP EPS of -$0.55 misses by $0.02 |
| 2025-05-09 | -9.5% | news | Seeking Alpha | Lisata outlines data-rich year ahead with multiple clinical milestones for Certepetide |
| 2025-05-09 | -9.5% | earnings | Seeking Alpha | Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript |
| 2025-05-08 | -9.3% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-05-05 | -8.8% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-04-15 | +8.6% | news | Seeking Alpha | Lisata Therapeutics announces research license with Catalent |
| 2022-09-29 | +8.6% | legal | SEC EDGAR | LSTA 8-K: 8.01 (SEC Filing) |
| 2022-09-29 | +8.6% | news | Stock Titan | Latest LSTA News - Lisata Therapeutics Enters into Definitive ... - Stock Titan |
| 2023-11-02 | +8.5% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-23 | -6.8% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | Lisata Therapeutics (LSTA) Market Dynamics | Lisata Therapeutics posts 10.2% EPS beat, 170B revenue - Expert Entry Points - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-02-28 | +6.8% | M&A | The Globe and Mail | Lisata Extends Kuva Labs Acquisition Term Sheet Timeline - The Globe and Mail |
| 2024-05-09 | +6.6% | earnings | Seeking Alpha | Lisata Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation |
| 2024-05-09 | +6.6% | earnings | Seeking Alpha | Lisata Therapeutics GAAP EPS of -$0.65 beats by $0.07 |
| 2024-05-09 | +6.6% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-09-05 | +5.3% | legal | Seeking Alpha | Lisata jumps on FDA orphan drug status for bile duct cancer drug |
| 2024-05-08 | +5.2% | earnings | Seeking Alpha | Lisata Therapeutics Q1 2024 Earnings Preview |
| 2021-11-04 | -5.1% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-08-06 | -4.8% | earnings | Seeking Alpha | Lisata Therapeutics Q2 2025 Earnings Preview |
| 2022-02-25 | -4.7% | legal | SEC EDGAR | LSTA 8-K: 5.02 (SEC Filing) |
| 2024-05-10 | -4.6% | earnings | Seeking Alpha | Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript |
| 2023-05-01 | +4.3% | legal | SEC EDGAR | LSTA 8-K: 5.02 (SEC Filing) |
| 2025-11-05 | -4.1% | earnings | Seeking Alpha | Lisata Therapeutics Q3 2025 Earnings Preview |
| 2023-03-30 | +3.9% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-11-12 | -3.5% | earnings | Seeking Alpha | Lisata Therapeutics GAAP EPS of -$0.59 beats by $0.16 |
| 2024-11-12 | -3.5% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-09-22 | -3.5% | legal | SEC EDGAR | LSTA 8-K: 7.01, 8.01 (SEC Filing) |
| 2021-05-06 | -3.5% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-02-29 | -3.2% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-06-29 | +3.1% | legal | Stock Titan | LSTA SEC Filings - Lisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2024-11-13 | -2.8% | earnings | Seeking Alpha | Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript |
| 2024-08-13 | -2.6% | earnings | Seeking Alpha | Lisata Therapeutics, Inc. (LSTA) Q2 2024 Earnings Call Transcript |
| 2025-08-13 | -2.6% | news | simplywall.st | Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans? - simplywall.st |
| 2022-03-22 | -2.5% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-06-04 | +2.5% | legal | SEC EDGAR | LSTA 8-K: 1.01 and (SEC Filing) |
| 2025-06-17 | -2.3% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-07-15 | -2.2% | legal | SEC EDGAR | LSTA 8-K: 8.01 and (SEC Filing) |
| 2024-06-27 | +2.0% | legal | SEC EDGAR | LSTA 8-K: 2.02 (SEC Filing) |
| 2025-10-08 | -1.9% | legal | SEC EDGAR | LSTA 8-K: 1.01 (SEC Filing) |
| 2025-10-08 | -1.9% | expansion | Investing.com | Lisata Therapeutics enters non-exclusive license agreement with Catalent - Investing.com |
| 2025-05-07 | +1.9% | earnings | Seeking Alpha | Lisata Therapeutics Q1 2025 Earnings Preview |
| 2025-06-13 | -1.8% | legal | SEC EDGAR | LSTA 8-K: 5.02 and (SEC Filing) |
| 2024-12-03 | -1.8% | expansion | Seeking Alpha | Lisata Therapeutics and Kuva Labs announce global license agreement for solid tumor imaging |
| 2024-12-03 | -1.8% | legal | SEC EDGAR | LSTA 8-K: 1.01 (SEC Filing) |
| 2024-12-03 | -1.8% | expansion | GlobeNewswire | Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging - GlobeNewswire |
| 2022-11-10 | -1.7% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-08-08 | -1.7% | earnings | Seeking Alpha | Lisata extends cash runway into Q4 2026 while advancing certepetide development milestones |
| 2025-08-08 | -1.7% | earnings | Seeking Alpha | Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript |
| 2022-08-05 | -1.6% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-07-18 | -1.6% | news | Seeking Alpha | Lisata to use Haystack technology to evaluate pancreatic cancer asset certepetide |
| 2022-10-20 | -1.6% | analyst | ChartMill | LSTA Forecast, Price Target & Analyst Ratings | LISATA THERAPEUTICS INC (NASDAQ:LSTA) - ChartMill |
| 2025-02-26 | +1.5% | earnings | Seeking Alpha | Lisata Therapeutics FY 2024 Earnings Preview |
| 2026-01-22 | +1.4% | news | Yahoo Finance | Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance |
| 2022-10-04 | +1.3% | legal | SEC EDGAR | LSTA 8-K: 8.01 and (SEC Filing) |
| 2024-04-13 | -1.2% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2024-04-17 | +1.1% | legal | SEC EDGAR | LSTA 8-K: 5.02 (SEC Filing) |
| 2024-08-12 | -1.0% | earnings | Seeking Alpha | Lisata Therapeutics GAAP EPS of -$0.61 beats by $0.14 |
| 2024-08-12 | -1.0% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-06-11 | -0.9% | executive | Stock Titan | Lisata CEO to Reveal Latest Cancer Treatment Developments at Major Biotech Conference - Stock Titan |
| 2026-04-04 | -0.9% | M&A | The Globe and Mail | Lisata Therapeutics Delays Tender Offer Launch in Merger - The Globe and Mail |
| 2026-04-03 | -0.9% | legal | SEC EDGAR | LSTA 8-K: 8.01 and (SEC Filing) |
| 2021-08-05 | -0.8% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-02 | -0.8% | expansion | Stock Titan | Lisata Therapeutics (LSTA) and Kuva Labs delay tender offer launch to April 13 - Stock Titan |
| 2023-02-06 | +0.7% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2025-05-01 | -0.5% | earnings | Stock Titan | Lisata Therapeutics Earnings: Solid Tumor Treatment Developer Reports Q1 2025 Results May 8 - Stock Titan |
| 2023-08-14 | -0.5% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-02-27 | -0.4% | earnings | Seeking Alpha | Lisata Therapeutics GAAP EPS of -$2.40 beats by $0.22, revenue of $1M |
| 2025-02-27 | -0.4% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-09 | -0.3% | legal | SEC EDGAR | LSTA 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-27 | -0.3% | legal | SEC EDGAR | LSTA 8-K: 1.01 and (SEC Filing) |
| 2024-11-11 | +0.2% | earnings | Seeking Alpha | Lisata Therapeutics Q3 2024 Earnings Preview |
| 2023-07-11 | +0.2% | legal | SEC EDGAR | LSTA 8-K: 5.02 (SEC Filing) |
| 2026-03-10 | +0.1% | M&A | Minichart | Lisata Therapeutics to Be Acquired by Kuva Labs for $5.00 Per Share Plus Potential $1.00 CVR in 2026 Merger Deal - Minichart |
| 2022-10-06 | -0.0% | news | GlobeNewswire | Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022 - GlobeNewswire |
| 2026-04-24 | — | news | MEXC Exchange | LSTA Price Today: Lisata Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange |